How savvy KOL engagement can drive marketing and sales
This article was originally published in Scrip
A shrewd understanding of how key opinion leadership is changing can help companies drive better launch and marketing campaigns for their drugs. Increasingly strained, localized and patient-centric healthcare systems mean that the days of simply appointing a clinician to write about a drug or present at meetings to raise its profile are gone. To get the help with advocacy and marketing they want, firms must change their strategies and engage with a wider array of KOLs, explains Leyla Hannbeck, head of pharmacy at the National Pharmacy Association.
You may also be interested in...
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.